

LIST OF PARTICIPANTS

Members¹

Bruce C. Baguley

Auckland Cancer Society Research Centre
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019 Auckland
New Zealand

Frederick A. Beland

Division of Biochemical Toxicology
National Center for Toxicological Research
Jefferson, Arkansas 72079
USA

Elizabeth Barrett-Connor

Department of Family and Preventive
Medicine
Division of Epidemiology
University of California San Diego
La Jolla, CA 92093
USA

Martin R. Berger

Toxicology and Chemotherapy Unit
German Cancer Research Centre
69120 Heidelberg
Germany

¹ Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited specialists are marked by an asterisk.

Each participant was asked to disclose pertinent research, employment, and financial interests. Current financial interests and research and employment interests during the past 3 years or anticipated in the future are identified here. Minor pertinent interests are not listed and include stock valued at no more than US\$10 000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are listed as significant pertinent interests

Judy L. Bolton (unable to attend)

Department of Medicinal Chemistry and
Pharmacognosy
College of Pharmacy
University of Illinois at Chicago
Chicago, IL 60612-7231
USA

David Eastmond²

Environmental Toxicology Graduate
Program
Department of Cell Biology and Neuroscience
University of California
Riverside, CA 92521-0314
USA

Maarten C. Bosland

Department of Pathology
College of Medicine
University of Illinois at Chicago
Chicago, IL 60612
USA

Charles William Jameson (retired)³

National Institute of Environmental Health
Sciences
National Institute of Health
Research Triangle Park, NC 27709
USA

Joseph F. Buell

Division of Transplantation
Jewish Hospital Transplant Center
The Liver Tumor Institute
Louisville, Kentucky 40202
USA

John Kaldor⁴

National Centre in HIV Epidemiology and
Clinical Research
University of New South Wales
Darlinghurst, New South Wales 2010
Australia

² Dr Eastmond is receiving research funding from Pfizer (which markets contraceptives that are alternatives to those based on estrogen-progestogen combinations). Until 2006 he received research support from Johnson & Johnson (which markets estrogen-progestogen contraceptives through its Ortho subsidiary).

³ Dr Jameson in retired from and continues to consult for NIEHS/NTP.

⁴ Over the past five years Dr Kaldor has overseen a project funded by a grant from F. Hoffmann-La Roche to his University that led to the establishment of a clinical facility in Cambodia. None of his professional compensation is derived from F. Hoffmann-La Roche. That company also provided a drug for a study funded by the U.S. National Institutes of Health for which Dr Kaldor is the principal investigator. Dr Kaldor also will receive research support from Johnson & Johnson. In addition, Dr Kaldor serves as deputy director for his university's National Centre in HIV Epidemiology and Clinical Research, which receives approximately 10% of its funding from companies that make drugs under consideration at this meeting or that are alternatives to drugs under consideration. Such companies include F. Hoffmann-La Roche, Bristol-Myers Squibb, Pfizer, and Johnson & Johnson.

Peter Karran

Cancer Research UK
London Research Institute
Clare Hall Laboratories
South Mimms, Herts EN6 3LD
United Kingdom

Anthony B. Miller

Professor Emeritus
Lalla Dana School of Public Health
University of Toronto
Oakville, Ontario L6J 1J8
Canada

David G. Kaufman⁵

Department of Pathology and Laboratory
Medicine
University of North Carolina at Chapel Hill
Chapel Hill, NC 27599
USA

Alfredo A. Molinolo

Oral and Pharyngeal Cancer Branch
National Institute of Dental and
Craniofacial Research
Bethesda, MD 20892
USA

Seung-Hee Kim (unable to attend)

Department of Toxicological Research
National Institute of Toxicological Research
Korea Food and Drug Administration
Seoul 122-704
Republic of Korea

Jørgen H. Olsen

Danish Cancer Society
Institute of Cancer Epidemiology
2100 Copenhagen
Denmark

M. Matilde Marques

Department of Chemical and Biological
Engineering
Graduate Technical Institute
Technical University of Lisbon
1049-001 Lisbon
Portugal

David H. Phillips⁶

Institute of Cancer Research
Sutton, Surrey SM2 5NG
United Kingdom

⁵Dr Kaufman inherited shares in Schering-Plough (which markets estrogen-progestogen contraceptives and menopause treatments through its Organon subsidiary) and received research support from them until 2005. His institution will receive payment (under \$10 000) from Wyeth (which markets estrogen-progestogen menopausal treatments and is involved in several related lawsuits) for endometrial cells developed in his laboratory.

⁶Dr Phillips has been approached to consult for Movetis NV (which develops drugs for gastro-intestinal disorders under license from two subsidiaries of Johnson & Johnson, which manufactures estrogen-progestogen contraceptives).

Charles A. Schiffer

Division of Hematology/Oncology
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, MI 48201
USA

Heinz H. Schmeiser

Division of Molecular Toxicology
German Cancer Research Center
69120 Heidelberg
Germany

*Linda Titus-Ernstoff*⁷

Department of Community & Family
Medicine and Pediatrics
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756
USA

David B. Thomas

Program in Epidemiology
Fred Hutchinson Cancer Research Center
Seattle, WA 98109
USA

*Hiroyuki Tsuda*⁸

Nanotoxicology Project
Nagoya City University
Nagoya 467-8603
Japan

Observers

Michael G. Bird

Toxicology & Environmental Sciences
Division
ExxonMobil Biomedical Sciences, Inc.
Annandale, New Jersey 08801
USA

IARC Secretariat

Robert Baan (*Rapporteur, Mechanistic and
Other Relevant Data*)
Lamia Benbrahim-Tallaa (*Rapporteur,
Cancer in Experimental Animals*)
Véronique Bouvard (*Rapporteur,
Mechanistic and Other Relevant Data*)
Rafael Carel (*Visiting Scientist*)
Shu-Chun Chuang
Vincent Cogliano (*Head of Programme*)
Elisabeth Couto
Fatiha El Ghissassi (*Rapporteur,
Mechanistic and Other Relevant Data*)
Laurent Galichet (*Editor*)
Yann Grosse (*Responsible Officer*)
Neela Guha (*Rapporteur, Cancer in
Humans*)
Béatrice Lauby-Secretan (*Rapporteur,
Cancer in Humans*)
Yuan-Chin Amy Lee
Kurt Straif (*Rapporteur, Cancer in Humans*)
He Wang

⁷Dr Titus-Ernstoff received compensation (not exceeding \$1000 in total) from the Weinberg Group (a product-defence consulting firm) for writing a review of DES-related health outcomes during 2006-2007. She also contributes (without compensation) to occasional articles in DES-advocacy newsletters.

⁸Dr Tsuda is a non-industry member of the Board of Trustees of the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute, whose member companies are from the chemical, agrochemical, petrochemical, pharmaceutical, biotechnology, and consumer products industries.

Pre-meeting Scientific Assistance

Ted Junghans
Bethesda, MD
USA

Steve Olin
Washington, DC
USA

Post-Meeting Scientific Assistance

Crystal Freeman

Administrative Assistance

Sandrine Egraz
Michel Javin
Brigitte Kajo
Helene Lorenzen-Augros
Karine Racinoux

Production Team

Elisabeth Elbers
Anne-Sophie Hameau
Sylvia Moutinho
Dorothy Russell

